[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"RiboX Therapeutics Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":78},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100651745","phase-1-phase-1-dose-escalation-study-of-rxim002-in-autoimmune-cytopenias-100651745",false,"NCT07765966","Phase 1 Dose Escalation Study of RXIM002 in Autoimmune Cytopenias","A Phase 1, Open Label, Dose Escalation Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Early Efficacy of RXIM002, in Patients With Relapsed or Refractory Autoimmune Cytopenias","POPULUS-1","Inclusion Criteria:\n\n* 18-75 years of age\n* Diagnosed with primary ITP\n* Relapsed or refractory ITP\n\nExclusion Criteria:\n\n* Allergy or hypersensitivity to messenger ribonucleic acid (mRNA) vaccines or other RNA-LNP products\n* Any active infection\n* Heart failure, reduced kidney function, or liver abnormalities","ALL","18 Years","75 Years",{"count":21,"type":22},27,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","The Phase 1 is to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of RXIM002 in patients with relapsed or refractory autoimmune cytopenias.",[28,29],"Relapsed or Refractory Autoimmune Cytopenias","Immune Thrombocytopenia (ITP)",[31,29,32,33,34,35],"Relapsed or refractory autoimmune cytopenias","Circular ribonucleic acid","Chimeric Antigen Receptor (CAR)","Anti-human CD19","in vivo CAR-T therapy","NOT_YET_RECRUITING","2026-08-10",{"date":39,"type":40},"2026-08-14","ACTUAL",{"date":42,"type":22},"2027-02-01",{"date":44,"type":22},"2029-12-31",{"name":46,"class":47},"RiboX Therapeutics Ltd.","INDUSTRY",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},"100570977","phase-1-study-of-circular-rna-treatment-in-patients-with-radiation-induced-xerostomia-1-100570977","NCT06714253","Study of Circular RNA Treatment in Patients With Radiation Induced Xerostomia-1","A Phase I\u002FIIa, Dose Escalation Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of Intraductal Administration of RXRG001 to Parotid Gland(s) in Adults With Radiation-Induced Xerostomia and Hyposalivation","SPRINX-1","Inclusion Criteria\\*\n\n1. At least 18 years of age\n2. Free from recurrence of your cancer and never have had another form of cancer for at least 2 years\n3. Suffering from xerostomia and\u002For hyposalivation and have xerostomia symptoms which were not resolved after treatment for at least 3 months\n4. Both parotid glands on imaging examination\n\nExclusion Criteria\\*\n\n1. Any active infection\n2. Heart failure, reduced kidney function or uncontrolled diabetes (Hemoglobin A1c \\>=8%)\n3. History of autoimmune diseases known to potentially affect the salivary glands\n4. Any malignancy, other than head and neck cancer within the past 3 years except for certain skin and cervical cancers\n5. Active smoker or use tobacco products or have a history of substance or alcohol abuse\n\n   * Other criteria apply",{"count":57,"type":22},42,[25,59],"PHASE2","This is a first-in-human clinical study to evaluate the safety, tolerability and efficacy of RXRG001 administered in the ducts of the parotid glands in adult patients with radiation-induced xerostomia (dry mouth) and hyposalivation (reduced saliva production).\n\nIn Part 1 of the study (open-label, single-arm), patients will receive unilateral administrations of RXRG001 in 3 single ascending dose cohorts and in 3 multiple ascending dose cohorts.\n\nPart 2 of the study has a randomized, double-blind, placebo-controlled design. Patients will receive bilateral administrations of RXRG001 in 3 multiple ascending dose cohorts.",[62],"Radiation-Induced Xerostomia and Hyposalivation",[64,65,66,32,67],"Radiation Induced Xerostomia","First-in-human","Hyposalivation","Aquaporin 1","RECRUITING","2026-07-28",{"date":71,"type":40},"2026-07-29",{"date":73,"type":40},"2025-03-05",{"date":75,"type":22},"2027-08",{"name":46,"class":47},4,""]